These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 33966455)
1. Eplerenone Improves Pulmonary Vascular Remodeling and Hypertension by Inhibition of the Mineralocorticoid Receptor in Endothelial Cells. Kowalski J; Deng L; Suennen C; Koca D; Meral D; Bode C; Hein L; Lother A Hypertension; 2021 Aug; 78(2):456-465. PubMed ID: 33966455 [TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoid receptor antagonism improves parenchymal arteriole dilation via a TRPV4-dependent mechanism and prevents cognitive dysfunction in hypertension. Diaz-Otero JM; Yen TC; Fisher C; Bota D; Jackson WF; Dorrance AM Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1304-H1315. PubMed ID: 30118343 [TBL] [Abstract][Full Text] [Related]
3. Impact of mineralocorticoid receptor blockade with direct renin inhibition in angiotensin II-dependent hypertensive mice. Hashimoto A; Takeda Y; Karashima S; Kometani M; Aono D; Demura M; Higashitani T; Konishi S; Yoneda T; Takeda Y Hypertens Res; 2020 Oct; 43(10):1099-1104. PubMed ID: 32398797 [TBL] [Abstract][Full Text] [Related]
4. Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. Boehm M; Arnold N; Braithwaite A; Pickworth J; Lu C; Novoyatleva T; Kiely DG; Grimminger F; Ghofrani HA; Weissmann N; Seeger W; Lawrie A; Schermuly RT; Kojonazarov B BMC Pulm Med; 2018 Mar; 18(1):41. PubMed ID: 29499691 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023 [TBL] [Abstract][Full Text] [Related]
6. Regulation of myogenic tone and structure of parenchymal arterioles by hypertension and the mineralocorticoid receptor. Pires PW; Jackson WF; Dorrance AM Am J Physiol Heart Circ Physiol; 2015 Jul; 309(1):H127-36. PubMed ID: 25910805 [TBL] [Abstract][Full Text] [Related]
7. Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling. Elinoff JM; Chen LY; Dougherty EJ; Awad KS; Wang S; Biancotto A; Siddiqui AH; Weir NA; Cai R; Sun J; Preston IR; Solomon MA; Danner RL Cardiovasc Res; 2018 Jan; 114(1):65-76. PubMed ID: 29036418 [TBL] [Abstract][Full Text] [Related]
8. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats. Du J; Fan YY; Hitomi H; Kiyomoto H; Kimura S; Kong CZ; Noma T; Kohno M; Nishiyama A; Nakano D Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572 [TBL] [Abstract][Full Text] [Related]
9. Mineralocorticoid receptor antagonists and endothelial function. Maron BA; Leopold JA Curr Opin Investig Drugs; 2008 Sep; 9(9):963-9. PubMed ID: 18729003 [TBL] [Abstract][Full Text] [Related]
11. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Maron BA; Zhang YY; White K; Chan SY; Handy DE; Mahoney CE; Loscalzo J; Leopold JA Circulation; 2012 Aug; 126(8):963-74. PubMed ID: 22787113 [TBL] [Abstract][Full Text] [Related]
12. Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity. Hullin R; Métrich M; Sarre A; Basquin D; Maillard M; Regamey J; Martin D Cardiovasc Res; 2018 Feb; 114(2):272-281. PubMed ID: 29016737 [TBL] [Abstract][Full Text] [Related]
14. Aldosterone-induced oxidative stress and inflammation in the brain are mediated by the endothelial cell mineralocorticoid receptor. Dinh QN; Young MJ; Evans MA; Drummond GR; Sobey CG; Chrissobolis S Brain Res; 2016 Apr; 1637():146-153. PubMed ID: 26923165 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure. George J; Struthers AD Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity. Lother A; Bergemann S; Kowalski J; Huck M; Gilsbach R; Bode C; Hein L Cardiovasc Res; 2018 Feb; 114(2):282-290. PubMed ID: 28430882 [TBL] [Abstract][Full Text] [Related]